Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia.

Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, Bartzokis G, Aravagiri M.

Am J Psychiatry. 2001 Nov;158(11):1835-42.

PMID:
11691689
2.

Depot fluphenazine decanoate and enanthate for schizophrenia.

David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD000307. Review. Update in: Cochrane Database Syst Rev. 2015;2:CD000307.

PMID:
15674872
3.

Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia.

Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J.

Arch Gen Psychiatry. 1982 Jan;39(1):70-3.

PMID:
6275811
4.

Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.

Uchida T, Suzuki T, Sakurai H, Tsutsumi C, Den R, Mimura M, Uchida H.

Int Clin Psychopharmacol. 2013 Sep;28(5):261-6. doi: 10.1097/YIC.0b013e328363aa5a.

PMID:
23820334
5.

Low neuroleptic serum levels in patients receiving fluphenazine decanoate.

Tune LE, Creese I, Coyle JT, Pearlson G, Snyder SH.

Am J Psychiatry. 1980 Jan;137(1):80-2.

PMID:
6101523
6.

A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse.

Steingard S, Allen M, Schooler NR.

J Clin Psychiatry. 1994 Nov;55(11):470-2.

PMID:
7989278
8.

Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia.

Marder SR, Wirshing WC, Van Putten T, Mintz J, McKenzie J, Johnston-Cronk K, Lebell M, Liberman RP.

Arch Gen Psychiatry. 1994 Apr;51(4):280-7.

PMID:
8161288
9.

Early hospital experience with fluphenazine decanoate.

Small JG, Kellams J.

Dis Nerv Syst. 1974 Oct;35(10):453-6.

PMID:
17894058
10.
11.

Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.

Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M.

Arch Gen Psychiatry. 1997 Jan;54(1):49-55.

PMID:
9006400
12.

Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.

Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Lann HD, Breier AF, Summerfelt AT.

Am J Psychiatry. 1999 Mar;156(3):412-8.

PMID:
10080557
13.

A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.

Inderbitzin LB, Lewine RR, Scheller-Gilkey G, Swofford CD, Egan GJ, Gloersen BA, Vidanagama BP, Waternaux C.

Am J Psychiatry. 1994 Dec;151(12):1753-9.

PMID:
7977881
14.

Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.

Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.

J Psychiatry Neurosci. 1994 Jul;19(4):254-64. Review.

15.

[Comparison between the effectiveness of fluphenazine decanoate and oxyprothepin decanoate in schizophrenia (double-blind crossover study)].

Balon R, Kabesh Ia, Papezhova G.

Zh Nevropatol Psikhiatr Im S S Korsakova. 1982;82(1):116-8. Russian.

PMID:
6121437
16.

A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.

Chouinard G, Annable L, Campbell W.

J Clin Psychopharmacol. 1989 Aug;9(4):247-53.

PMID:
2570086
17.
18.

Two-year trial of maintenance neuroleptic dose reduction in schizophrenic out-patients: predictors of relapse.

Heresco-Levy U, Greenberg D, Lerer B, Dasberg H, Brown WA.

Isr J Psychiatry Relat Sci. 1995;32(4):268-75.

PMID:
8641856
19.

Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics.

Mandel MR, Severe JB, Schooler NR, Gelenberg AJ, Mieske M.

Arch Gen Psychiatry. 1982 Feb;39(2):197-203.

PMID:
6121543
20.

Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.

Odejide OA, Aderounmu AF.

J Clin Psychiatry. 1982 May;43(5):195-6.

PMID:
7076630

Supplemental Content

Support Center